Truist analyst Jailendra Singh upgraded Veeva (VEEV) to Buy from Hold with a $275 price target Market share shifts in the top 20 pharma have largely played out, with migration-related revenue impacts likely deferred beyond FY27, the analyst tells investors in a research note. Combined with strong execution in growth areas like Crossix and early AI traction, Veeva is positioned for durable growth and margin stability, making current valuations attractive from a risk/reward perspective, the firm argues.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VEEV: